Skip to content

ΕτικέταEli Lilly

Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals?

Even though Amgen and Novartis rolled out their hot new migraine drug, Aimovig, at a lower-than-expected price of $6,900, the companies expected pushback from payers, and they prepared for that … Continue Reading Will payers support Amgen’s ‘bolus’ of eager Aimovig patients in time to fend off migraine rivals?

Top 10 M&A Deals of January—June 2018 Value of Mergers and Acquisitions, Volume of Transactions, on Pace to Surpass 2017

    EY’s projection that the volume of mergers and acquisitions (M&A) in “life sciences”—which includes biopharma and medical technology segments—will go well past last year’s $200 billion annual volume of … Continue Reading Top 10 M&A Deals of January—June 2018 Value of Mergers and Acquisitions, Volume of Transactions, on Pace to Surpass 2017